Bristol-Myers Squibb Company (BMY) : The total negative money flow of $3.1 million on Thursday indicates selling on strength. The inflow of money on upticks was $24.25 million, compared to $27.35 million outflow on downticks, which confirms distribution in the stock. The up to down ratio was 0.89. The negative money flow of $2.44 million in block trades reveals that the informed traders sold the stock on every bit of price strength. The traded value of the stock on uptick was $0.89 million in a block trade.The transaction value of block trade on downtick was $3.33 million. The uptick to downtick ratio was 0.27. The price action in the Bristol-Myers Squibb Company (BMY) stock suggests that both the bulls and the bears were in equilibrium. The stock traded at $73.88 with a gain of $0.02 , a change of 0.03% over the previous days close. The stock registered 0.14% for the week.
Bristol-Myers Squibb Company (BMY) : The most positive equity analysts on Bristol-Myers Squibb Company (BMY) expects the shares to touch $100, whereas, the least positive believes that the stock will trade at $48 in the short term. The company is covered by 14 Wall Street Brokerage Firms. The average price target for shares are $73.86 with an expected fluctuation of $13.47 from the mean. The stock has recorded a 20-day Moving Average of 2.79% and the 50-Day Moving Average is 3.57%.
Bristol-Myers Squibb Company (NYSE:BMY): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $73.85 and $73.63 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $74.15. The buying momentum continued till the end and the stock did not give up its gains. It closed at $74.08, notching a gain of 0.30% for the day. The total traded volume was 4,056,693 . The stock had closed at $73.86 on the previous day.
Bristol-Myers Squibb Company (BMS) is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products across the world. The Companys products are sold to wholesalers, retail pharmacies, hospitals, government entities and the medical profession. The Company manufactures its products in the United States, Puerto Rico and in six foreign countries. The Company promotes the use of its products directly to healthcare professionals and providers, such as doctors, nurse practitioners, physician assistants, pharmacists, technologists, hospitals, Pharmacy Benefit Managers (PBMs) and Managed Care Organizations (MCOs). It also provides information about the use of its products to consumers in the United States through direct-to-consumer print, radio, television, and digital advertising and promotion. In addition, the Company holds rights to F001287, which is a preclinical, small-molecule IDO1-inhibitor.